emailContact Us    ASIP Members Access    Become a Supporter    News    Job Seekers/Employers    facebookGoogle+twitterinstagramlinkedinflickr

PISA 2016

Donate to ASIP

ASIP Companion Meeting at USCAP 2016 Annual meeting

“The Pathologist and the Development of Targeted Therapies"
Sunday, March 13, 2016, 1:30 PM - 5:00 PM

At the USCAP 2016 Annual Meeting, Seattle, WA, March 12-18, 2016


  • Maria J. Merino, MD, National Cancer Institute, Bethesda, MD

  • Danny A. Milner, MD, MSc, Brigham and Women's Hospital, Boston, MA

  • Mark E. Sobel, MD, PhD, American Society for Investigative Pathology, Bethesda, MD

Download Coming Soon

1:30 PM -1:35 PM Introduction to the ASIP Companion Meeting
Mark E. Sobel, MD, PhD, American Society for Investigative Pathology, Bethesda, MD
1:35 PM - 2:15 PM Integrated Morphologic and Molecular Glioma Diagnostics Based on the 2016 WHO Classification Scheme
Arie Perry, MD, University of California, San Francisco, San Francisco, CA
2:15 PM - 3:00 PM Cancer Immunotherapy: The Role of the Pathologist in the Oncology Team
James C. Yang, MD, National Cancer Institute, Bethesda, MD
3:00 PM - 3:30 PM

3:30 PM - 4:15 PM Immune Targeting in Breast Cancer
Ashley Cimino-Mathews, MD, The Johns Hopkins Hospital, Baltimore, MD
4:15 PM - 5:00 PM Benchtop to Bedside: Evolution of Molecular Classification of Lung Cancer
Neal Lindeman, MD, Brigham and Women's Hospital, Boston, MA


Statement for ACCME:
The topic was determined by the ASIP Education Committee.

Statement of Need: The integration of anatomic, molecular, and genomic pathology into surgical pathology practice is conspicuous in oncology, where definition of molecular pathways important for specific tumors has enabled development of drugs and innovative immunological approaches to target these pathways, and companion tests to predict which tumors are likely to respond to these targeted agents. The role of the surgical pathologist as part of the oncologic healthcare team is rapidly evolving. This session will focus on targeted therapies for melanoma and cancers of the brain, breast, and lung.

Target Audience: This activity has been designed to meet the educational needs of anatomic pathologists and other health care professionals who are involved in diagnosing, managing, and treating patients with disorders of the lung, pancreas, prostate, and tubal gut.

Learning Objectives: Upon completion of this activity, participants should be better able to:

  • Describe the new morphologic and molecular classification scheme of gliomas.
  • Describe approaches to cancer immunotherapies.
  • Describe immune targeting in breast cancer.
  • Describe the evolving molecular classification of lung cancer.